Navigation Links
Mylan's Matrix Obtains License for Promising HIV/AIDS Treatment
Date:1/27/2011

PITTSBURGH, Jan. 27, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has signed an agreement with Tibotec Pharmaceuticals for a non-exclusive license to manufacture, market and distribute a generic version of the non-nucleoside reverse transcriptase inhibitor Rilpivirine Hydrochloride (TMC278), pending its regulatory approval for the treatment of treatment-naive HIV-1-infected adults. Matrix will have the right to market the product in sub-Saharan Africa, certain developing countries and India.

Mylan President Heather Bresch said: "This agreement represents additional recognition for Mylan's Matrix in the antiretroviral (ARV) market, in which Matrix is a leader. It also marks a significant step toward the future access of this important new product being developed by Tibotec Pharmaceuticals for patients living with HIV/AIDS. By obtaining this license at this time, we can now begin our research and development phase for our formulation to ensure that a generic version will be available in developing countries as quickly as possible. This was an important step in ensuring that novel ARV treatments available in more fortunate countries are accessible to patients in need all over the world."

Under the agreement, Matrix will be entitled to manufacture once-daily 25 mg TMC278 as a single agent medicine and a fixed-dose combination (FDC) product. Fixed-dose combinations contain multiple medicines formulated into one tablet helping to simplify HIV therapy and are preferred by public health treatment programs.    

Prior to the signing of license agreements, TMC278 was submitted for regulatory approval in the U.S., Europe, Canada, Switzerland, Australia, Russia and South Korea. Upon approval, it is expected that TMC278, in combination with other ARV medicinal products, will be indicated for the treatment of HIV-1 infection in treatment-naive adult patients.

The agreement covers the manufacture of TMC278 as a single agent medicine and a license to develop a FDC product using TMC278 with 300 mg Tenofovir Disoproxil Fumarate and 300 mg Lamivudine, products which are already part of Matrix's ARV portfolio.

Matrix ranks among the world's leading producers of ARV products. Its ARV franchise includes active pharmaceutical ingredients and 34 first- and second-line finished doses, eight of which are pediatric products. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per patient of effective therapies. Approximately 30% of HIV/AIDS patients in developing countries depend on a Matrix ARV product.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
2. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
3. Matrixx Initiatives, Inc. Announces End of Go-Shop Period
4. Matrixx Initiatives, Inc. Summarizes Ongoing Go-Shop Process and Board Reaffirms Recommendation
5. Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share
6. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
7. Matrixx Initiatives, Inc. and H.I.G. Capital Announce Early Termination of HSR Waiting Period
8. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
9. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
10. National University Hospital Singapore Operates on Asias 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
11. Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
(Date:9/9/2017)... NEW YORK , Sept. 8, 2017 ... largest independent supplier of medical equipment, supplies, drugs, ... that it has entered into an agreement to acquire ... surgical equipment based in Holtsville, New York ... which specializes in supplying new and emerging medical practices, ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... 22, 2017 , ... MEDIA OPPORTUNITY: , Save Our Hospital - Albert Lea ... they are rallying against Mayo Clinic. Specifically, media can talk to steering committee members ... decision to close the Albert Lea hospital. , The rally aims to protect the ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... financial setbacks, a senior finds a new lease on life with assistance from ... of people resolve their problem with unsecured debt. The senior is one of ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with a Curse: ... tithe, and the freedom experienced when breaking free from this misconception. “Cursed with ... M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s new book ...
(Date:9/22/2017)... ... 22, 2017 , ... “Fruit of the Spirit: “Love””: a delightful adventure ... has created. “Fruit of the Spirit: “Love”” is the creation of published author, Halimah ... mother of five. Halimah is an avid writer, her inspiration for “Fruit of the ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from Pixel ... to do. Users can select from up to two layers of subject matter along ... a mouse all within Final Cut Pro X. , With ProSlideshow Portrait ...
Breaking Medicine News(10 mins):